Regeneron’s Dupixent® (dupilumab) is now indicated to treat patients at least six months of age who have moderate-to-severe atopic dermatitis that is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable. It was previously approved to treat atopic dermatitis only in patients at least six years of age.

• First FDA approved in 2017, Dupixent is also indicated to treat asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyposis.
• Recommended dosing for atopic dermatitis in children is based on the patient’s age and weight. Maintenance dosing can range from 200mg once every four weeks to 300mg once every two weeks. Dupixent is given by subcutaneous injection and can be administered at home.